First AD

Second AD

ASH 2024 Updates: inMIND study With Tafasitamab Combined With Lenalidomide and Rituximab in R/R FL 

Video content above is prompted by the following:

This year at ASH 2024, we had a late-breaking presentation on the primary analysis from the inMIND study with tafasitamab combined with lenalidomide and rituximab, which showed superiority to the current standard of care, lenalidomide and rituximab. What are the key highlights from this presentation, including efficacy and safety and your impressions? How do you anticipate this to impact your treatment approach in the 2L setting if approved?

Video Series

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Clinical Insights on R/R Follicular Lymphoma: ASH 2024 Highlights

Peer Exchange

Panelists discuss the key findings from the ASH 2024 late-breaking presentation on the inMIND study, highlighting the superior efficacy and safety of tafasitamab combined with lenalidomide and rituximab over the current standard of care, and how these results may impact treatment strategies in the second-line (2L) setting for relapsed/refractory follicular lymphoma, if approved.